Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 98

1.

Symptoms of Depression and Anxiety Are Independently Associated With Clinical Recurrence of Inflammatory Bowel Disease.

Mikocka-Walus A, Pittet V, Rossel JB, von Känel R; Swiss IBD Cohort Study Group.

Clin Gastroenterol Hepatol. 2016 Jun;14(6):829-835.e1. doi: 10.1016/j.cgh.2015.12.045. Epub 2016 Jan 25.

PMID:
26820402
2.

Quality of Life in Swiss Paediatric Inflammatory Bowel Disease Patients: Do Patients and Their Parents Experience Disease in the Same Way?

Mueller R, Ziade F, Pittet V, Fournier N, Ezri J, Schoepfer A, Schibli S, Spalinger J, Braegger C, Nydegger A; Swiss IBD Cohort Study.

J Crohns Colitis. 2016 Mar;10(3):269-76. doi: 10.1093/ecco-jcc/jjv199. Epub 2015 Oct 29.

PMID:
26519462
3.

Impact of the early use of immunomodulators or TNF antagonists on bowel damage and surgery in Crohn's disease.

Safroneeva E, Vavricka SR, Fournier N, Pittet V, Peyrin-Biroulet L, Straumann A, Rogler G, Schoepfer AM; Swiss IBD Cohort Study Group.

Aliment Pharmacol Ther. 2015 Oct;42(8):977-89. doi: 10.1111/apt.13363. Epub 2015 Aug 14.

PMID:
26271358
4.

Systematic analysis of factors associated with progression and regression of ulcerative colitis in 918 patients.

Safroneeva E, Vavricka S, Fournier N, Seibold F, Mottet C, Nydegger A, Ezri J, Straumann A, Rogler G, Schoepfer AM; Swiss IBD Cohort Study Group.

Aliment Pharmacol Ther. 2015 Sep;42(5):540-8. doi: 10.1111/apt.13307. Epub 2015 Jul 6. Erratum in: Aliment Pharmacol Ther. 2015 Dec;42(11-12):1334.

PMID:
26148503
5.

Analysis of TNF-antagonist switch over time and associated risk factors in the Swiss Inflammatory Bowel Disease Cohort.

Hiroz P, Vavricka SR, Fournier N, Safroneeva E, Pittet V, Rogler G, Schoepfer AM; Swiss Inflammatory Bowel Diseases Cohort Study Group.

Scand J Gastroenterol. 2014 Oct;49(10):1207-18. doi: 10.3109/00365521.2014.946082. Epub 2014 Aug 14.

PMID:
25120029
6.

Prevalence and clinical importance of mesenteric venous thrombosis in the Swiss Inflammatory Bowel Disease Cohort.

Violi NV, Schoepfer AM, Fournier N, Guiu B, Bize P, Denys A; Swiss Inflammatory Bowel Disease Cohort Study Group.

AJR Am J Roentgenol. 2014 Jul;203(1):62-9. doi: 10.2214/AJR.13.12447. Erratum in: AJR Am J Roentgenol. 2014 Aug;203(2):463.

PMID:
24951196
7.

Serum ficolin-2 correlates worse than fecal calprotectin and CRP with endoscopic Crohn's disease activity.

Schaffer T, Schoepfer AM, Seibold F; Swiss IBD Cohort Study Group.

J Crohns Colitis. 2014 Sep;8(9):1125-32. doi: 10.1016/j.crohns.2014.02.014. Epub 2014 Mar 11.

PMID:
24636141
8.

Appropriateness and long-term discontinuation rate of biological therapies in ulcerative colitis.

Maillard MH, Bortolotti M, Vader JP, Mottet C, Schoepfer A, Gonvers JJ, Burnand B, Froehlich F, Michetti P, Pittet V; Swiss IBD Cohort Study Group.

J Crohns Colitis. 2014 Aug;8(8):825-34. doi: 10.1016/j.crohns.2013.12.026. Epub 2014 Jan 22.

PMID:
24462322
9.

Diagnostic delay in Crohn's disease is associated with a complicated disease course and increased operation rate.

Schoepfer AM, Dehlavi MA, Fournier N, Safroneeva E, Straumann A, Pittet V, Peyrin-Biroulet L, Michetti P, Rogler G, Vavricka SR; IBD Cohort Study Group.

Am J Gastroenterol. 2013 Nov;108(11):1744-53; quiz 1754. doi: 10.1038/ajg.2013.248. Epub 2013 Aug 27.

PMID:
23978953
10.

The course of inflammatory bowel disease during pregnancy and postpartum: a prospective European ECCO-EpiCom Study of 209 pregnant women.

Pedersen N, Bortoli A, Duricova D, D Inca R, Panelli MR, Gisbert JP, Zoli G, López-Sanromán A, Castiglione F, Riegler G, Annese V, Gionchetti P, Prada A, Pont ED, Timmer A, Felley C, Shuhaibar M, Tsianos EV, Dejaco C, Baert FJ, Jess T, Lebech M, Hommes DW, Munkholm P; European Crohn-Colitis Organisation-ECCO-Study Group of Epidemiology Committee-EpiCom.

Aliment Pharmacol Ther. 2013 Sep;38(5):501-12. doi: 10.1111/apt.12412. Epub 2013 Jul 15.

11.

Penetrating or stricturing diseases are the major determinants of time to first and repeat resection surgery in Crohn's disease.

Pittet V, Rogler G, Michetti P, Fournier N, Vader JP, Schoepfer A, Mottet C, Burnand B, Froehlich F; Swiss Inflammatory Bowel Disease Cohort Study Group.

Digestion. 2013;87(3):212-21. doi: 10.1159/000350954. Epub 2013 May 23.

PMID:
23711401
12.

When do we dare to stop biological or immunomodulatory therapy for Crohn's disease? Results of a multidisciplinary European expert panel.

Pittet V, Froehlich F, Maillard MH, Mottet C, Gonvers JJ, Felley C, Vader JP, Burnand B, Michetti P, Schoepfer A; EPACT-II Update Panellists.

J Crohns Colitis. 2013 Nov;7(10):820-6. doi: 10.1016/j.crohns.2013.04.013. Epub 2013 May 9.

PMID:
23664620
13.

Predictors for hospitalization and outpatient visits in patients with inflammatory bowel disease: results from the Swiss Inflammatory Bowel Disease Cohort Study.

Sulz MC, Siebert U, Arvandi M, Gothe RM, Wurm J, von Känel R, Vavricka SR, Meyenberger C, Sagmeister M; Swiss IBD Cohort Study Group.

Eur J Gastroenterol Hepatol. 2013 Jul;25(7):790-7. doi: 10.1097/MEG.0b013e32836019b9.

PMID:
23571609
14.

Predictors of temporary and permanent work disability in patients with inflammatory bowel disease: results of the swiss inflammatory bowel disease cohort study.

Siebert U, Wurm J, Gothe RM, Arvandi M, Vavricka SR, von Känel R, Begré S, Sulz MC, Meyenberger C, Sagmeister M; Swiss IBD Cohort Study Group.

Inflamm Bowel Dis. 2013 Mar-Apr;19(4):847-55. doi: 10.1097/MIB.0b013e31827f278e.

PMID:
23446333
15.

Age, smoking and overweight contribute to the development of intestinal metaplasia of the cardia.

Felley C, Bouzourene H, VanMelle MB, Hadengue A, Michetti P, Dorta G, Spahr L, Giostra E, Frossard JL.

World J Gastroenterol. 2012 May 7;18(17):2076-83. doi: 10.3748/wjg.v18.i17.2076.

16.

Association of a common vitamin D-binding protein polymorphism with inflammatory bowel disease.

Eloranta JJ, Wenger C, Mwinyi J, Hiller C, Gubler C, Vavricka SR, Fried M, Kullak-Ublick GA; Swiss IBD Cohort Study Group.

Pharmacogenet Genomics. 2011 Sep;21(9):559-64. doi: 10.1097/FPC.0b013e328348f70c.

PMID:
21832969
17.

Epidemiology of inflammatory bowel disease: Is there a shift towards onset at a younger age?

Braegger CP, Ballabeni P, Rogler D, Vavricka SR, Friedt M, Pittet V; Swiss IBD Cohort Study Group.

J Pediatr Gastroenterol Nutr. 2011 Aug;53(2):141-4. doi: 10.1097/MPG.0b013e318218be35.

PMID:
21788753
18.

Efficacy and safety of certolizumab pegol in an unselected crohn's disease population: 26-week data of the FACTS II survey.

Vavricka SR, Schoepfer AM, Bansky G, Binek J, Felley C, Geyer M, Manz M, Rogler G, de Saussure P, Sauter B, Scharl M, Seibold F, Straumann A, Michetti P; Swiss IBDnet.

Inflamm Bowel Dis. 2011 Jul;17(7):1530-9. doi: 10.1002/ibd.21521. Epub 2010 Dec 22.

PMID:
21674709
19.

Systematic evaluation of risk factors for diagnostic delay in inflammatory bowel disease.

Vavricka SR, Spigaglia SM, Rogler G, Pittet V, Michetti P, Felley C, Mottet C, Braegger CP, Rogler D, Straumann A, Bauerfeind P, Fried M, Schoepfer AM; Swiss IBD Cohort Study Group.

Inflamm Bowel Dis. 2012 Mar;18(3):496-505. doi: 10.1002/ibd.21719. Epub 2011 Apr 20.

PMID:
21509908
20.

Appropriate management of special situations in Crohn's disease (upper gastro-intestinal; extra-intestinal manifestations; drug safety during pregnancy and breastfeeding): Results of a multidisciplinary international expert panel-EPACT II.

Mottet C, Vader JP, Felley C, Froehlich F, Gonvers JJ, Juillerat P, Stockbrügger R, Angelucci E, Seibold F, Michetti P, Pittet V; EPACT II Study Group.

J Crohns Colitis. 2009 Dec;3(4):257-63. doi: 10.1016/j.crohns.2009.03.008. Epub 2009 May 14.

PMID:
21172284
Items per page

Supplemental Content

Loading ...
Write to the Help Desk